BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27282579)

  • 21. Initial frequency of CD34+/CD38 - cells is not correlated with minimal residual disease level in 73 Chinese children with B-cell precursor acute lymphoblastic leukemia.
    Feng JH; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Xu WQ
    Leuk Lymphoma; 2013 Sep; 54(9):2073-5. PubMed ID: 23323948
    [No Abstract]   [Full Text] [Related]  

  • 22. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.
    Vergez F; Green AS; Tamburini J; Sarry JE; Gaillard B; Cornillet-Lefebvre P; Pannetier M; Neyret A; Chapuis N; Ifrah N; Dreyfus F; Manenti S; Demur C; Delabesse E; Lacombe C; Mayeux P; Bouscary D; Recher C; Bardet V
    Haematologica; 2011 Dec; 96(12):1792-8. PubMed ID: 21933861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group.
    Dworzak MN; Gaipa G; Schumich A; Maglia O; Ratei R; Veltroni M; Husak Z; Basso G; Karawajew L; Gadner H; Biondi A
    Cytometry B Clin Cytom; 2010 May; 78(3):147-53. PubMed ID: 20201055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia.
    Wang W; Gao L; Li Y; Li ZL; Gong M; Huang FZ; Chen YR; Zhang CX; Gao YY; Ma YG
    Leuk Lymphoma; 2016 May; 57(5):1174-81. PubMed ID: 26436205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
    Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry.
    Muzzafar T; Medeiros LJ; Wang SA; Brahmandam A; Thomas DA; Jorgensen JL
    Am J Clin Pathol; 2009 Nov; 132(5):692-8. PubMed ID: 19846809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
    Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
    Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.
    Angelova E; Audette C; Kovtun Y; Daver N; Wang SA; Pierce S; Konoplev SN; Khogeer H; Jorgensen JL; Konopleva M; Zweidler-McKay PA; Medeiros LJ; Kantarjian HM; Jabbour EJ; Khoury JD
    Haematologica; 2019 Apr; 104(4):749-755. PubMed ID: 30361418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [CD34(+)CD19(+) cells with CD123 overexpression are a novel prognostic marker in Ph chromosome-positive acute lymphoblastic leukemia].
    Kong Y; Huang XJ; Hao L; Qin YZ; Jiang Q; Jiang H; Liu YR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):6-10. PubMed ID: 24598641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The knowledge on the 3rd type hematogones could contribute to more precise detection of small numbers of precursor B-acute lymphoblastic leukemia.
    Babusíková O; Zelezníková T; Mlcáková A; Kusenda J; Stevulová L
    Neoplasma; 2005; 52(6):502-9. PubMed ID: 16284697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: a study of five cases controlled by genetic methods.
    Dworzak MN; Stolz F; Fröschl G; Printz D; Henn T; Fischer S; Fleischer C; Haas OA; Fritsch G; Gadner H; Panzer-Grümayer ER
    Exp Hematol; 1999 Apr; 27(4):673-81. PubMed ID: 10210325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic significance of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell lymphoblastic leukemia without minimal residual disease.
    Liao H; Zheng Q; Jin Y; Chozom T; Zhu Y; Liu L; Jiang N
    Sci Rep; 2019 Dec; 9(1):19722. PubMed ID: 31871314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deciphering stage 0 hematogones by flow cytometry in follow-up bone marrow samples of pediatric B-Acute lymphoblastic leukemia cases: A potential mimicker of residual disease after anti CD19 therapy.
    Ramalingam TR; Vaidhyanathan L; Muthu A; Swaminathan VV; Uppuluri R; Raj R
    Cytometry B Clin Cytom; 2024 Mar; 106(2):92-98. PubMed ID: 38243626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application and prognostic relevance of CD34 detection in immunophenotyping of pediatric acute B lymphoblastic leukemia.
    Zha W; Yuan Y; Yang T; Zhu LJ; Kong WY; Zhuo JJ
    Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3384-3390. PubMed ID: 38766795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
    Roug AS; Larsen HØ; Nederby L; Just T; Brown G; Nyvold CG; Ommen HB; Hokland P
    Br J Haematol; 2014 Jan; 164(2):212-22. PubMed ID: 24152218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Expression of CD58 in childhood B-lineage acute lymphoblastic leukemia and its feasibility in minimal residual disease detection].
    Li YF; Zhao XM; Sheng GY; Yue BH; Luo Y
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Aug; 17(8):825-9. PubMed ID: 26287347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
    Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Easy discrimination of hematogones from lymphoblasts in B-cell progenitor acute lymphoblastic leukemia patients using CD81/CD58 expression ratio.
    Nagant C; Casula D; Janssens A; Nguyen VTP; Cantinieaux B
    Int J Lab Hematol; 2018 Dec; 40(6):734-739. PubMed ID: 30113764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping.
    Bras AE; de Haas V; van Stigt A; Jongen-Lavrencic M; Beverloo HB; Te Marvelde JG; Zwaan CM; van Dongen JJM; Leusen JHW; van der Velden VHJ
    Cytometry B Clin Cytom; 2019 Mar; 96(2):134-142. PubMed ID: 30450744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.